Last reviewed · How we verify
Rivaroxaban or Marcumar
Rivaroxaban is a direct Factor Xa inhibitor that prevents blood clot formation by blocking a key enzyme in the coagulation cascade, while Marcumar (phenprocoumon) is a vitamin K antagonist that inhibits clotting factor synthesis.
Rivaroxaban is a direct Factor Xa inhibitor that prevents blood clot formation by blocking a key enzyme in the coagulation cascade, while Marcumar (phenprocoumon) is a vitamin K antagonist that inhibits clotting factor synthesis. Used for Atrial fibrillation for stroke prevention, Deep vein thrombosis (DVT) treatment and prevention, Pulmonary embolism (PE) treatment and prevention.
At a glance
| Generic name | Rivaroxaban or Marcumar |
|---|---|
| Also known as | Xarelto; Marcumar |
| Sponsor | RWTH Aachen University |
| Drug class | Anticoagulant (Rivaroxaban: direct Factor Xa inhibitor; Marcumar: vitamin K antagonist) |
| Target | Factor Xa (Rivaroxaban); Vitamin K epoxide reductase complex (Marcumar) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Rivaroxaban selectively inhibits Factor Xa, a serine protease essential for thrombin generation and clot formation, providing rapid anticoagulation. Marcumar works through a different mechanism by antagonizing vitamin K-dependent clotting factors (II, VII, IX, X), requiring several days to achieve full effect. These are distinct anticoagulant classes with different pharmacokinetics and monitoring requirements.
Approved indications
- Atrial fibrillation for stroke prevention
- Deep vein thrombosis (DVT) treatment and prevention
- Pulmonary embolism (PE) treatment and prevention
- Acute coronary syndrome (Rivaroxaban only)
Common side effects
- Bleeding (major and minor)
- Gastrointestinal bleeding
- Intracranial hemorrhage
- Dyspepsia
- Elevated liver enzymes
Key clinical trials
- Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy (PHASE4)
- Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)
- Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)
- Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)
- Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral Anticoagulants (NOACs) vs. Phenprocoumon
- Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification (PHASE4)
- Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients
- COMBO-Stent in Patients on Chronic Anticoagulant Therapy (COSTA) COSTA-Bleed and COSTA-Outcome Trials (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rivaroxaban or Marcumar CI brief — competitive landscape report
- Rivaroxaban or Marcumar updates RSS · CI watch RSS
- RWTH Aachen University portfolio CI